The good times roll for Dice
The company raises hopes that its oral IL-17 inhibitor could rival Sotyktu, but there are reasons to be cautious.
Lilly’s oral interleukin exit hints at a dicey future
Liver toxicity with the group’s oral IL-17 inhibitor could raise doubts about projects from Dice, Leo and Sanofi.
Aclaris’s second crack at a topical Jak
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
AAD 2020 – Leo’s eczema wildcard proves tame
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
Lilly jumps the gun with Dermira deal
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
